Loading...
Triplet therapy with an immunomodulatory drug, a proteasome inhibitor, and dexamethasone has improved response and progression-free survival in patients with multiple myeloma.
To test the activity of the oral proteasome inhibitor ixazomib in myeloma triplet therapy, investigators conducted an industry-sponsored, multicenter, randomized, double-blind, placebo-controlled phase III trial comparing lenalidomide plus dexamethasone with either ixazomib or placebo in 772 patients with relapsed or refractory disease.
At a median follow-up of 14.7 months, progression-free survival (the primary endpoint) was significantly longer with the ixazomib-containing triplet regimen versus the placebo regimen (20.6 vs. 14.7 months; P=0.01), although overall resp…